# Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

> **NCT04836832** · PHASE1 · WITHDRAWN · sponsor: **Narendranath Epperla**

## Conditions studied

- Recurrent Follicular Lymphoma
- Recurrent Marginal Zone Lymphoma
- Recurrent Nodal Marginal Zone Lymphoma
- Recurrent Splenic Marginal Zone Lymphoma
- Refractory Follicular Lymphoma
- Refractory Indolent Non-Hodgkin Lymphoma
- Refractory Marginal Zone Lymphoma
- Refractory Nodal Marginal Zone Lymphoma
- Refractory Splenic Marginal Zone Lymphoma

## Interventions

- **DRUG:** Acalabrutinib
- **DRUG:** Duvelisib

## Key facts

- **NCT ID:** NCT04836832
- **Lead sponsor:** Narendranath Epperla
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-07-01
- **Primary completion:** 2023-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** PI decision
- **Last updated:** 2022-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04836832

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04836832, "Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04836832. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*